Drug intelligence / Profile preview

GHB-006

Development stage: Preclinical
Lead developer: Gatehouse Bio
Modality: Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

GHB-006 is a preclinical-stage therapeutic candidate being developed by Gatehouse Bio for the treatment of Inflammatory Bowel Disease (IBD). Developed using Gatehouse Bio's AI-driven platform, which identifies small RNA (sRNA) signatures associated with disease states, GHB-006 is designed to modulate specific biological pathways involved in intestinal inflammation. As of early 2024, the program remains in the preclinical phase of development.

Beyond the preview

Go deeper on GHB-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GHB-006.

Explore the full profile